Oncternal Therapeutics Inc
NASDAQ:ONCT 4:00:00 PM EDT
| Market Cap (Intraday) | 25.45M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $8.81 |
| 50-Day MA | $8.96 |
| 200-Day MA | $7.76 |
Oncternal Therapeutics Inc Stock, NASDAQ:ONCT
12230 El Camino Real, Suite 230, San Diego, California 92130
United States of America
Phone: +1.858.434.1113
Number of Employees: 27
Description
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.